logo-loader
viewAvacta Group PLC

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst Ed Stacey

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space.

The group's reported interim results to January 2019 today, revealing revenues of £1.0mln and illustrating good progress on its key development programmes.

Quick facts: Avacta Group PLC

Price: 16.5 GBX

AIM:AVCT
Market: AIM
Market Cap: £29.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avacta Plc 'making significant progress towards commercialising Affimer...

Capital Network analyst Riccardo Lowi discusses Avacta Group Plc (LON:AVCT) following the release of its preliminary results. Lowi says over the last year or so, management's delivered significant progress in bringing their Affimer platform into the commercial stage, across both...

on 10/04/2018

RNS

Holding(s) in Company

2 weeks, 5 days ago

Director/PDMR Shareholding

3 weeks, 2 days ago

Holding(s) in Company

on 11/11/2019

Holding(s) in Company

on 11/08/2019

Holding(s) in Company

on 11/08/2019

Holding(s) in Company

on 11/07/2019

Holding(s) in Company

on 11/07/2019

2 min read